Monday, March 31, 2014

High-Platelet Reactivity and Stroke

Nevio Taglieri, and his colleagues from the University of Bologna (Bologna, Italy), conducted a meta-analysis of 14 studies (collectively enrolling 11,959 patients) to evaluate the risk of stroke in patients who had platelet testing while undergoing percutaneous coronary intervention (PCI). Among the studies included in the meta-analysis, prevalence of high platelet reactivity was 30% ±15% (range, 6% to 67%). As expected, prevalence of platelet hyperactivity was higher in studies using VerifyNow than in those using light-transmission aggregometery (LTA) (42% ±13% vs 22% ±10%; P = 0.006). Overall, the annual stroke rate was 0.9%. After pooled analysis, the risk of stroke was higher in patients with high platelet reactivity than in those without (1.2% vs 0.7%; RR 1.84; 95% CI 1.21-2.80).

The study provides interesting insights: first, it confirms the role of platelet aggregation in the athero-thrombo-embolic phenomena. Secondly, it suggests that there is a group of people who, despite having complete (near complete) blockage of P2Y12 receptors, may have higher activity through other platelet aggregation pathways and may benefit from a different drug. Of note, most patients in this meta-analysis were already on clopidogrel and aspirin, two of the several platelet aggregation pathways.

No comments: